The PRAME
Leader
Since its foundation, Immatics has been relentlessly focused on building its scientific approach from the ground up to develop and deliver novel PRAME immunotherapies for patients with cancer.
Today, Immatics is the global leader in the precision targeting of PRAME, a target expressed in more than 50 cancers, and has the broadest PRAME franchise with the most PRAME indications and modalities.
Quick Facts
~700
TEAM
MEMBERS
in Tübingen and Munich, Germany and Houston, Texas
3
GLOBAL
SITES
4
CLINICAL
PROGRAMS
2
THERAPEUTIC
MODALITIES
TCR-T and TCR Bispecifics in clinical development
2
TECHNOLOGY
PLATFORMS
for target and TCR discovery
200+
TARGETS
across major solid tumors